Comparison of ticagrelor and clopidogrel in anemic patients with acute coronary syndrome: efficacy and safety outcomes over one year

dc.authorid POLAT, FUAT/0000-0002-6414-3743
dc.authorid Yaylak, Baris/0000-0001-5863-4039
dc.authorid AKYUZ, SUKRU/0000-0003-2596-6875
dc.authorscopusid 8835640500
dc.authorscopusid 57211459355
dc.authorscopusid 36678592800
dc.authorscopusid 36103971300
dc.authorscopusid 57221697878
dc.authorscopusid 57201468365
dc.authorwosid POLAT, FUAT/C-7556-2019
dc.contributor.author Onuk, Tolga
dc.contributor.author Polat, Fuat
dc.contributor.author Yaylak, Baris
dc.contributor.author Akyuz, Sukru
dc.contributor.author Kolak, Zeynep
dc.contributor.author Durak, Furkan
dc.contributor.other Kardiyoloji / Cardiology
dc.date.accessioned 2024-05-25T11:37:37Z
dc.date.available 2024-05-25T11:37:37Z
dc.date.issued 2024
dc.department Okan University en_US
dc.department-temp [Onuk, Tolga; Polat, Fuat; Yaylak, Baris; Kolak, Zeynep] Dr Siyami Ersek Thorac & Cardiovasc Surg Educ Res, Dept Cardiol, Selimiye Mah Tbbiye Cad 25 skdar, Istanbul, Turkiye; [Akyuz, Sukru] Okan Univ, Dept Cardiol, Fac Hlth Sci, Istanbul, Turkiye; [Durak, Furkan] Prof Dr İlhan Varank Sancaktepe Training & Re, Dept Cardiol, Istanbul, Turkiye en_US
dc.description POLAT, FUAT/0000-0002-6414-3743; Yaylak, Baris/0000-0001-5863-4039; AKYUZ, SUKRU/0000-0003-2596-6875 en_US
dc.description.abstract ObjectiveThis retrospective study aimed to investigate the potential impact of ticagrelor and clopidogrel treatment on cardiovascular outcomes in patients with anemia and acute coronary syndrome (ACS) and to provide insights into the optimal therapeutic approach for this vulnerable patient population.MethodsA retrospective research design was employed, involving patients diagnosed with ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) between 2014 and 2021. Inclusion criteria required a hemoglobin level below 12 mg/dL and a minimum 12-month P2Y12 inhibitor treatment. Comprehensive clinical, biochemical, and echocardiographic data were collected from the hospital's electronic repository. The primary efficacy endpoint was major adverse cardiovascular events (MACE), encompassing total mortality, cardiovascular mortality, reinfarction, ischemic stroke, and hemorrhagic stroke. Major hemorrhage was the primary safety endpoint. Secondary outcomes included total mortality, cardiovascular mortality, reinfarction, ischemic stroke, and hemorrhagic stroke, individually.ResultsPatients treated with ticagrelor (n = 118) and clopidogrel (n = 538) were compared. No significant difference was observed in major adverse cardiovascular events (MACE) and major bleeding between ticagrelor and clopidogrel treatment groups (MACE: clopidogrel 10.0% vs. ticagrelor 11.0%, p = 0.75; major bleeding: clopidogrel 2.8%, ticagrelor 2.5%, p = 0.88). Patients with hemoglobin levels <= 8 mg/dL demonstrated significantly higher MACE and major bleeding rates in the ticagrelor group (p = 0.008 and p = 0.002, respectively). Among patients aged >= 75 years, ticagrelor treatment was associated with a higher risk of major bleeding (p = 0.04).ConclusionsTicagrelor and clopidogrel exhibited comparable efficacy and safety outcomes in anemic ACS patients over a one-year period. Although ticagrelor demonstrated superiority in reducing ischemic events, it is crucial to recognize the limitations of retrospective studies in informing clinical practice. This study offers valuable insights into tailoring antiplatelet therapy for anemic ACS patients and provides guidance for personalized treatment strategies, acknowledging the hypothesis-generating nature of retrospective analyses. en_US
dc.identifier.citationcount 0
dc.identifier.doi 10.1007/s00228-024-03653-1
dc.identifier.endpage 770 en_US
dc.identifier.issn 0031-6970
dc.identifier.issn 1432-1041
dc.identifier.issue 5 en_US
dc.identifier.pmid 38360988
dc.identifier.scopus 2-s2.0-85185132743
dc.identifier.scopusquality Q2
dc.identifier.startpage 759 en_US
dc.identifier.uri https://doi.org/10.1007/s00228-024-03653-1
dc.identifier.uri https://hdl.handle.net/20.500.14517/1198
dc.identifier.volume 80 en_US
dc.identifier.wos WOS:001162138400001
dc.identifier.wosquality Q3
dc.language.iso en
dc.publisher Springer Heidelberg en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.scopus.citedbyCount 0
dc.subject Ticagrelor en_US
dc.subject Clopidogrel en_US
dc.subject Anemia en_US
dc.subject Acute coronary syndrome en_US
dc.title Comparison of ticagrelor and clopidogrel in anemic patients with acute coronary syndrome: efficacy and safety outcomes over one year en_US
dc.type Article en_US
dc.wos.citedbyCount 0

Files